Release Date: 3/31/2025
Expiration Date: 3/31/2026
Activity Overview
Biologic agents targeting the IL-23/IL-17 axis have demonstrated improved efficacy compared to conventional therapies and include several US Food and Drug Administration (FDA) approved agents for the treatment of PsO: (1) anti-IL-23, ie, tildrakizumab-asmn, guselkumab, and risankizumab-rzaa, (2) anti-IL-12/IL-23, ie, ustekinumab, (3) anti-IL-17A, ie, ixekizumab, secukinumab, and brodalumab, and (4) anti-IL-17A and F, ie, bimekizumab-bkzx.
The purpose of this Burst CME continuing education program is to increase the knowledge of clinicians on the key therapeutic targets within the IL-23/IL-17 pathway and the role of therapeutic monoclonal antibodies directed against these key targets in the management of psoriasis. The mechanisms of action, efficacy, safety, and limitations of these agents will also be discussed by expert faculty Dr Tina Bhutani, as well as identifying patients who would optimally benefit from anti-IL-17 and IL-23 therapies via improvement of long- term outcomes and quality of life.
Target Audience
This educational activity is directed toward dermatologists, internists, NPs, PAs, RNs, and other HCPs involved in the management of psoriasis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the association between the IL-23/TH17 inflammatory pathway and the pathogenesis of PsO
- Implement prescribing strategies for the incorporation of IL-17 or IL-23 mAbs in the treatment of PsO based on long-term clinical evidence
Tina Bhutani, MD
Associate Professor of Dermatology
Co-Director, Psoriasis and Skin Treatment Center
University of California, San Francisco
CEO
Synergy Dermatology
San Francisco, CA
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.